Molecular Oncology and Drug Discovery Program, Parker Hughes Institute, St. Paul, MN, USA.
Br J Haematol. 2010 Jun;149(6):865-73. doi: 10.1111/j.1365-2141.2010.08177.x. Epub 2010 Apr 4.
This study compared the gene expression profiles of primary leukaemic cells from infants versus children with acute lymphoblastic leukaemia (ALL). Our analyses provided unprecedented evidence that remarkably different pathognomonic transcriptomes dominate the biology of infant versus paediatric high risk ALL. The genetic signature of infant ALL is characterized by concomitant overexpression of mitogenic and anti-apoptotic genes, some of which have been associated with early relapse in ALL. Our study demonstrated that primary leukaemia cells from infant ALL patients expressed significantly higher levels of genes for cytokines that mediate their biological effects through stimulation of the JAK-STAT signal transduction pathway including interleukin 1a, interleukin 1b, interleukin 2, and interleukin 7. We further showed that the JAK/STAT signalling pathway is constitutively active in CD10(-) infant ALL cells and treatment with a JAK3 inhibitor or a pan-JAK kinase inhibitor effectively triggered their apoptosis. These findings identified JAK3 as an attractive molecular target for disrupting the constitutively deregulated anti-apoptotic STAT3 and STAT5 signalling pathways in infant ALL cells.
本研究比较了婴儿与儿童急性淋巴细胞白血病(ALL)原始白血病细胞的基因表达谱。我们的分析提供了前所未有的证据,表明婴儿与儿科高危 ALL 的生物学特性明显由截然不同的特征性转录组主导。婴儿 ALL 的遗传特征是有丝分裂原和抗凋亡基因的同时过度表达,其中一些与 ALL 的早期复发有关。我们的研究表明,婴儿 ALL 患者的原始白血病细胞表达更高水平的细胞因子基因,这些基因通过刺激 JAK-STAT 信号转导途径发挥其生物学效应,包括白细胞介素 1a、白细胞介素 1b、白细胞介素 2 和白细胞介素 7。我们进一步表明,CD10(-) 婴儿 ALL 细胞中的 JAK/STAT 信号通路持续激活,JAK3 抑制剂或泛 JAK 激酶抑制剂的治疗可有效触发其凋亡。这些发现确定 JAK3 是一个有吸引力的分子靶点,可破坏婴儿 ALL 细胞中持续失调的抗凋亡 STAT3 和 STAT5 信号通路。